Hope Tribune

Non-Small Cell Lung Cancer Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight

 Breaking News
  • No posts were found

Non-Small Cell Lung Cancer Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight

April 20
23:59 2022
Non-Small Cell Lung Cancer Market Is Expected To Grow During The Forecast Period (2019-2032), DelveInsight

DelveInsight’s Non-Small Cell Lung Cancer Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Non-Small Cell Lung Cancer market share of the individual therapies, current and forecasted Non-Small Cell Lung Cancer market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

 

Non-Small Cell Lung Cancer Overview

NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas.

 

Some of the key highlights of the Non-small cell lung cancer market report

  • The United States had 227,875 incident cases of Lung Cancer in 2020, of which ~85%, i.e., 193,694 were NSCLC cancer patients.
  • According to DelveInsight’s data, about 7 out of 10 patients in the United States had metastatic NSCLC stage IIIb and IV.
  • DelveInsight’s analysts have estimated that in 2020, in the United States there were over 38,000 incident cases for EGFR mutation.
  • NSCLC market companies are included like Novartis pharmaceuticals, Abbvie, Janssen pharmaceuticals, Eli Lilly and Company, Sanofi, Pfizer, Astellas pharma, Takeda pharmaceuticals, Merck pharmaceuticals, GSK, Amgen, Incyte Corporation, and many others.
  • NSCLC therapies are included like Nazartinib/EGF816, Capmatinib/INC280, Telisotuzumab Vedotin, JNJ-61186372/JNJ-6372, Ensartinib/X-396, SAR408701, Selpercatinib (LY3527723/LOXO-292), and many others.

 

Download sample report- https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market

 

Non-Small Cell Lung Cancer Symptoms includes

  • Fatigue
  • Cough
  • Shortness of breath
  • Chest pain
  • Loss of appetite
  • Coughing up blood
  • Unintentional weight loss

 

Non-Small Cell Lung Cancer Treatment includes-

Currently the mainstay of treatment is immune checkpoint inhibitors, combination of targeted and immunotherapy with chemotherapy. Although in future, scenario is going to be changed as most of the companies are targeting specific mutations to treat the NSCLC patients. The growth of NSCLC Market is expected to be driven by increasing incident case of NSCLC, continue uptake of approved therapies mainly immune checkpoint inhibitors, expected entry of potential premium price emerging therapies and increasing awareness of mutations like BRAF, c-Met and others; currently there is a lack of potential treatment options for these mutations but now companies are working thoroughly towards the development of mutation specific therapies.

 

Non-Small Cell Lung Cancer Market Barriers

  • High Cost and Cost-effectiveness of therapies
  • Small patient populations for specific subsets of NSCLC
  • Generic or biosimilar erosion

 

Non-Small Cell Lung Cancer Market Drivers

  • Increasing use of biomarker testing
  • Increasing Incidence of Lung Cancer
  • Increase in the mutation specific trials activity and approval

 

Non-Small Cell Lung Cancer Market Report Scope

  • The report covers the descriptive overview of Non-Small Cell Lung Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Non-Small Cell Lung Cancer epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Non-Small Cell Lung Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Non-Small Cell Lung Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Non-Small Cell Lung Cancer market.

 

Non-Small Cell Lung Cancer Companies

  • Novartis pharmaceuticals,
  • Abbvie,
  • Janssen pharmaceuticals,
  • Eli Lilly and Company,
  • Sanofi,
  • Pfizer,
  • Astellas pharma,
  • Takeda pharmaceuticals,
  • Merck pharmaceuticals,
  • GSK,
  • Amgen,
  • Incyte Corporation,
  • And many others.

 

Non-Small Cell Lung Cancer Drugs

  • Nazartinib/EGF816,
  • Capmatinib/INC280,
  • Telisotuzumab Vedotin,
  • JNJ-61186372/JNJ-6372
  • Ensartinib/X-396,
  • SAR408701,
  • Selpercatinib (LY3527723/LOXO-292),
  • And many others.

 

Get detailed information about the therapies @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market

 

Table of content

  1. Key Insights
  2. Executive Summary of NSCLC
  3. SWOT Analysis of NSCLC
  4. NSCLC: Market Overview at a Glance
  5. Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
  6. Diagnosis of NSCLC
  7. Epidemiology and Patient Population
  8. EU-5 Epidemiology
  9. Japan Epidemiology
  10. Current Treatment Practices: NSCLC
  11. Guideline of NSCLC
  12. Unmet Needs of NSCLC
  13. Key Endpoints in NSCLC Clinical Trials
  14. Marketed Therapies
  15. Emerging Therapies
  16. Non-Small Cell Lung Cancer (NSCLC): Seven Major Market Analysis
  17. PD-L1—Market Size
  18. BRAF Mutation—Market Size
  19. c-MET Mutation—Market Size
  20. EGFR Mutation—Market Size
  21. ALK-Mutation—Market Size
  22. Market Access and Reimbursement of NSCLC Therapies
  23. Market Drivers of NSCLC
  24. Market Barriers of NSCLC
  25. Appendix
  26. DelveInsight Capabilities
  27. Disclaimer
  28. About DelveInsight

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/